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treatment patterns, prices and data availability. This study aims
at developing a model to overcome these challenges and to
combine epidemiology and economic data to estimate the cost
of MS in Europe. METHODS: A model was developed, based
on the prevalence of the disease and the cost per patient for dif-
ferent degrees of severity of disease, with the following purposes:
1) transform and convert available economic data to a deﬁned
time period as well as currency; 2) adjust country speciﬁc eco-
nomic data for purchasing power and relative size of economy;
3) impute data for countries where no data are available; and 4)
combine epidemiology and economic data to estimate the total
cost of a deﬁned disease. The model was populated with Euro-
pean published data on multiple sclerosis. National and inter-
national statistics for the model were retrieved from the OECD
and Eurostat databases. The estimates were presented in Euro
for 2003. RESULTS: The estimated cost for MS in Europe is
10.7€ billion. Mild patients with MS accounted for 53% of the
total cost, moderate 25% and severe patients for 22%. The high
income countries accounted for 77% of the total cost and the
countries with high prevalence in MS constituted 80% of the
total cost. The model estimates for drug costs were validated
against other data on total costs for MS drugs in Europe. CON-
CLUSIONS: The model provides a novel approach to estimat-
ing the cost of illness of a disease in Europe, as illustrated with
the example of MS.
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OBJECTIVES: The lack of epidemiological data has suggested
to perform an Italian retrospective study with the objective to
assess the health resources consumption that are caused by
acromegalic cure and the relative co-morbidities in order to esti-
mate the amount of the direct cost of acromegalic patients.
METHODS: A retrospective study has been performed on a total
of 134 patients (142 patients selected, 76 patients by site of
Genoa and 66 patients by the site of Turin) for a period of about
7 years preceding the enrolment date. For the observation study
period all hospitalizations (ordinary hospitalization and Day-
Hospital), all specialist visits and diagnostic and laboratory tests
have been collected, for each patient, from the relative medical
records independently if the health care resources used were due
to the primary disease or to co-morbidities. Only direct costs
have been evaluated by performing an analysis on the perspec-
tive of Italian Healthcare Service (SSN). RESULTS: The mean
total direct costs for acromegaly cure ranged from 8,526 to
12,546€ €/year (p = 0.008, Mann Whitney Test), respectively, for
controlled and not controlled patients. Pointing out that the cost
driver was represented by drug (somatostatin analogs) for
acromegalic cure, the not controlled patient group showed a
major use of drugs and the relative mean annual cost was about
1.66 times than that of controlled patient group (mean annual
drug cost 6,438€ ± 8993 in the controlled group vs 10,719€ ±
10,012 in not-controlled group; p = 0.012). CONCLUSION:
The study support the hypothesis that controlled patients drove
a saving for SSN in comparison to poor control patients that use
more health resources.
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OBJECTIVES: To quantify the differences in health-related
quality of life within and between adults with GHD and the
general population in Spain and England & Wales (E&W),
respectively, using the disease-speciﬁc instrument QoL—Assess-
ment of Growth Hormone Deﬁciency in Adults (QoL-AGHDA).
METHODS: QoL-AGHDA is a 25-item questionnaire that
elicits yes/no responses to personal statements describing prob-
lems that characterize aspects of HrQoL in growth hormone deﬁ-
ciency. A high QoL-AGHDA score denotes poor HrQoL. The
Spanish population sample comprised 940 individuals, and the
England and Wales sample 921. These survey data were collected
in studies reported elsewhere (Badia and Koltowska–Häggström,
respectively). Patient data were retrieved from KIMS (Pﬁzer
International Metabolic Database). The number of patients from
the two countries were 315 and 836, respectively. Student t-tests
were performed on mean data for groups formed by 10-year age
bands and gender. RESULTS: For Spain the mean QoL-AGHDA
was 11.0 for patients and 5.1 in the general population. For
E&W the corresponding means were 14.7 and 6.7. The mean
deﬁcits for patients compared with the general population were
similar in all age- and gender groups and were statistically sig-
niﬁcant (p < 0.0001). The mean patient QoL-AGHDA from
E&W were signiﬁcantly higher in most age and gender categories
compared with the Spanish patients (p < 0.05). The general pop-
ulation QoL-AGHDA scores in men did not differ signiﬁcantly
between countries (Spain = 5.9 vs. E&W = 6.2), but women from
Spain scored signiﬁcantly lower (higher HrQoL) than women
from E&W (3.9 vs. 7.0; p < 0.0001). CONCLUSIONS: This
study conﬁrms the extent of deﬁcit in HrQoL in adults with
GHD compared to general population. For patient comparisons,
caution is needed in interpreting these results, since the eligibil-
ity criteria for GH replacement differ between the two countries.
The reasons for gender variability between Spain and E&W
general population requires further studies.
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OBJECTIVE: Adequate treatment of patients with overactive
bladder (OAB) depends signiﬁcantly on the rate of persistence
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with prescribed drug therapy, such as antimuscarinic agents. We
evaluated cost-effectiveness outcomes associated with toltero-
dine extended release (TER), oxybutynin immediate release
(OIR), and no active drug treatment in Germany and the UK
(UK). METHODS: A decision-analytic model was developed for
the analysis. The primary endpoint was cost-effectiveness per
patient achieving persistent control (continuing therapy 6
months after initial prescription). A large case-controlled study
(N = 10,041 per arm) was used to estimate persistence. Resource
uses included in the model were the cost of drugs, regular physi-
cian visits, incontinence pads, and the cost of urinary tract and
skin infections. These were for controlled and uncontrolled
OAB. Costs were estimated from the perspective of the health
care systems of Germany and the UK. Sensitivity analyses
included variation of the time horizon of the analysis, unit costs,
and outcomes achieved. Cost-effectiveness ﬁgures were con-
verted to EUR2004 at market rates. RESULTS: The expected
number of patients achieving persistent control at 6 months was
44% with TER and 20% with OIR. The expected cost-effec-
tiveness per patient during 6 months in Germany was 420.89€
with TER, 224.54€ with OIR, and 51.13€ with no treatment; in
the UK, respective costs were 439.20€, 292.60€, and 23.30€. The
incremental cost-effectiveness per patient achieving persistent
control for TER compared with no treatment was 951.70€ in the
UK and 846.13€ in Germany, and compared with OIR, it was
608.28€ in the UK and 814.71€ in Germany. The model was
most sensitive to changes in the time horizon considered and
dose of drugs required. CONCLUSION: More than twice as
many patients achieved persistent control with TER than with
OIR. This persistence resulted in superior cost-effectiveness for
TER compared to OIR in both the UK and Germany.
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OBJECTIVES: Overactive bladder (OAB) is a common, chronic
and distressing medical condition that affects individuals of all
ages, and is associated with an increased risk of comorbidities.
Tolterodine is an antimuscarinic drug indicated for the treatment
of OAB, and is available as both an immediate-release (IR),
twice-daily, tablet formulation of tolterodine and extended-
release (ER), once-daily, capsule formulation. The aim of this
analysis is to carry out an economic evaluation of IR versus ER
tolterodine in the management of OAB in Spain. METHODS: A
cost-effectiveness analysis was performed by building a decision
analytic model. Efﬁcacy, tolerability and healthcare resource uti-
lization data were obtained from a double-blind, multicenter,
randomized trial showing that ER formulation was more effec-
tive and better tolerated than the IR formulation 1. Only direct
medical costs-drug acquisition, physician visits, diagnostic eval-
uations, incontinence pads and treatment of skin complications
and urinary tract infection-were taken into account. Drug costs
were obtained from ofﬁcial sources, and the rest of data were
taken from a national health care cost database. The perspective
selected for this analysis was primary care assistance and the time
horizon was 12 weeks, the treatment period in the referenced
clinical trial. RESULTS: The percentage of patients treated with
ER tolterodine had a greater control on OAB symptoms (71%
vs 60%, p < 0.05) and a lower cost/effectiveness ratio (375 vs
414€ per patient with successful outcome) than patients treated
with IR tolterodine. CONCLUSIONS: This model demonstrates
that ER tolterodine is a more efﬁcient therapeutic option than
IR tolterodine despite of the difference in acquisition costs
between the two formulations. Therefore, ER could be consid-
ered as the tolterodine formulation to be selected routinely in the
management of OAB in Spain. Van Kerrebroeck et al. Urology
57: 414–421, 2001.
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OBJECTIVE: Urinary tract infections (UTIs) often lead to recur-
rent episodes of UTI, which are generally treated with antibiotics
but the latter may induce bacterial resistance. URO-VAXOM®
in addition to antibiotics reduces the incidence and severity of
UTIs and improves treatment success. The objective of this deci-
sion analysis is to assess the economic impact of URO-
VAXOM® taken in addition to standard medication.
METHODS: A Markov model was developed for the analysis.
As the health outcome variables both symptom-free quarters and
disutilities due to UTIs were chosen. The model simulates the
course of recurrent UTI-patients over 4 consecutive quarters. A
recent randomised, multinational double-blind clinical trial con-
ducted in 52 centres was used to calculate the treatment effect
and the quarterly transition rates. Resource use included were
the cost for drugs, general practitioner and specialist visit costs.
Costs were estimated from the societal perspective within the
framework of the German health care system. Indirect costs for
absence from work were based on days off work reported in the
clinical trial. Sensitivity analyses included variation of the unit
costs and outcomes achieved. RESULTS: The Markov analysis
resulted in 2.82 total symptom-free quarters for the placebo
treatment group and 3.33 for the URO-VAXOM® treatment
group. The cumulated effect over 4 quarters for the quality-
adjusted life-years was 0.995 for the placebo treatment group
and 0.999 for the URO-VAXOM® treatment group. The incre-
mental cost effectiveness ratio (ICER) was 182€ for each addi-
tional symptom-free quarter generated and 23,500€ for each
additional quality-adjusted life-year in Germany. The ICER was
robust to variation of assumptions. CONCLUSION: Despite the
decline of antibiotic’s costs this economic analysis of the ran-
domised, double-blind clinical trial showed that adding URO-
VAXOM® to the standard treatment regimen has a favourable
cost-beneﬁt ratio, far below values internationally considered to
be cost-effective.
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OBJECTIVES: Overactive bladder (OAB) is a costly chronic
health condition affecting women and men of all ages. This study
assessed the relationship between patient perception of OAB
drug therapy success, and associated resource use. METHODS:
A descriptive, cross-sectional survey was conducted via the inter-
net in January 2004 in individuals diagnosed with and using
various therapies for OAB identiﬁed in the 2003 National Health
and Wellness Survey. Health care resource use in the previous 6
months was compared between those who considered themselves
